Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 118

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 118
---
 need to shut down or operate our Argentine Wet -Labat a minimum due to quarantine, disrupting our operations and product deliveries; •delays and/or cancellations of Rewell test kits and/or Heritas Diagnostics sample logistics, nutrigenetic coaching and/or medical geneticist appointments, and other operational procedures which may negatively affect orders for our products or services; •illness, quarantines, financial hardships, restrictions on travel and commerce, and supply chain disruptions, which may hinder our, and our suppliers’ and customers’, businesses and workforces; •periods of reduced demand from our diagnostic laboratory partners, which may cause us to suspend certain operations and/or services; and •abrupt changes to operating plans, which may seek to manage volatile conditions but may hinder our commercial and development activities. Any of the above occurrences could have an adverse impact on our business, financial condition, results of operations and growth prospects. Our operating results may fluctuate significantly and can be difficult to predict. Our operating results may be subject to significant fluctuations due to a variety of factors, including currency fluctuations, inflation, seasonal variations or non -seasonalevents, pricing of our tests, collection of payments from third -partyand other payers, success in marketing and selling our tests, research and development activities, negative publicity, customer and patient preferences, competitive conditions, and changes in overall spending levels in the life sciences industry. Our revenue is also subject to fluctuations due to the timing of sales of high -valueproducts and services, the effects of new product launches and related promotions, and the timing and availability of our customers’ funding. Fluctuations in our operating results could cause our performance in any particular period to fall below the expectations of securities analysts or investors, which could negatively affect the price of our ordinary shares. Furthermore, any reduction in the market price of our securities could make it more difficult for us to raise additional funds through future offerings of our shares or other securities. While we anticipate future growth, there is some uncertainty as to the timing of revenue on a quarterly basis. If we fail to maintain and successfully manage our strategic collaborations and third -party arrangements, such as the ones with CIBIC and Meyer, our future results may be adversely impacted. We currently have limited operational resources. In order to grow our business as planned, we must continue to enhance our sales, marketing and customer support capabilities, which will involve developing and administering our commercial infrastructure and/or collaborative commercial arrangements and partnerships. If we are unable to develop commercial infrastructure and enter into commercial agreements,